A second wave of trials in the Risperdal mass tort has been scheduled for October, and several more cases are gearing up for trials in the spring.
Two trials against Janssen Pharmaceuticals, the maker of the antipsychotic Risperdal, have been set to begin in October, and according to attorneys involved in the mass tort, pretrial discovery has begun in about 10 more cases. Trials in those cases have been tentatively set to begin in the spring.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
